Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

  • End date
    Oct 19, 2024
  • participants needed
  • sponsor
    ALX Oncology Inc.
Updated on 19 November 2021
squamous cell carcinoma
advanced head and neck squamous cell carcinoma


A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.


This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease. The study comprises of an initial safety lead-in followed by a randomized portion.

Condition Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, head and neck cancer, cancer of the head and neck, Squamous Cell Carcinoma of the Head and Neck, Head and Neck Squamous Cell Carcinoma
Treatment Pembrolizumab, ALX148, Cisplatin/Carboplatin; 5FU, Evorpacept
Clinical Study IdentifierNCT04675333
SponsorALX Oncology Inc.
Last Modified on19 November 2021


Yes No Not Sure

Inclusion Criteria

Previously untreated metastatic or unresectable, recurrent head and neck squamous cell carcinoma
Adequate bone marrow function
Adequate renal and liver function
Adequate ECOG performance status

Exclusion Criteria

Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids
History of (non-infectious) pneumonitis that required steroids or current pneumonitis
Prior treatment with any anti-CD47 or anti-SIRP agent
Prior treatment with anti-PD-1 or PD-L1
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note